Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The BSCL2 mRNA 3' untranslated region (3'UTR) is a key regulatory segment of the transcript encoding Seipin, a protein essential for lipid droplet biogenesis (UniProt Q8WUX1). Seipin is primarily localized in the endoplasmic reticulum, where it facilitates the budding of lipid droplets and maintains lipid homeostasis (PMID: 21730171). The 3'UTR of the BSCL2 mRNA contains specific sequences that serve as binding sites for microRNAs, such as miR-125b, which negatively regulate Seipin expression (PMID: 30563845). Mutations in the BSCL2 gene are the primary cause of Berardinelli-Seip congenital lipodystrophy type 2, a condition characterized by a lack of functional adipose tissue and severe insulin resistance (NCBI Gene: 11315). Additionally, certain gain-of-function mutations in BSCL2 lead to seipinopathies, a group of motor neuron diseases including Silver syndrome (PMID: 22431511). Targeting the 3'UTR allows for the modulation of Seipin protein levels without altering the genomic DNA, providing a potential therapeutic avenue for metabolic and neurological disorders. Experimental approaches using antisense oligonucleotides (ASOs) or microRNA modulators are being explored to either enhance or suppress Seipin production. This target is particularly relevant for biotech research focused on RNA-based therapeutics for rare genetic diseases and metabolic syndrome.
Modulation of protein expression by targeting regulatory elements within the 3' untranslated region to alter mRNA stability or translation efficiency.
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Berardinelli-Seip congenital lipodystrophy 2 mRNA 3' untranslated region (BSCL2 mRNA 3'UTR) (BSCL2 mRNA 3'UTR).